To hear about similar clinical trials, please enter your email below
Trial Title:
Immunohistochemical Expression of Inhibin Beta A (INHBA) in Colorectal Carcinoma
NCT ID:
NCT05794737
Condition:
Colorectal Cancer
Conditions: Official terms:
Carcinoma
Colorectal Neoplasms
Conditions: Keywords:
Inhibin Beta A
Colorectal Carcinoma
Immunohistochemistry
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Retrospective
Intervention:
Intervention type:
Biological
Intervention name:
Immunohistochemical staining
Description:
Staining of Colorectal Carcinoma tissue sections by monoclonal antibodies against human
Inhibin Beta A by immunohistochemical procedures.
Arm group label:
Participants
Summary:
A retrospective observational study to evaluate immunohistochemical expression of Inhibin
Beta A (INHBA) in 60 cases of Colorectal Carcinoma, and compare levels of its expression
to different clinicopathological criteria.
Detailed description:
Colorectal Carcinoma is an aggressive malignant epithelial tumor with an observable high
incidence. Tumor invasion and metastasis to distant sites are two important issues which
determine patient's outcome, so detecting novel biological markers that are involved in
tumor proliferation and invasion with subsequent targeting by future medical drugs will
positively improve patient's prognosis.
Inhibin Beta A (INHBA) is a glycoprotein molecule that has a role in tumor cells
proliferation and invasion in different human malignancies. The aim of this study is to
detect expression of INHBA in 60 archived formalin-fixed Paraffin-embedded tissue blocks
of patients suffered from Colorectal Carcinoma, and to correlate different levels of its
expression to some studied clinical and pathological criteria (Age, Sex, Tumor size,
location, depth of tumor invasion, status of regional lymph nodes, vascular and
perineural invasion).
Criteria for eligibility:
Study pop:
Archived Formalin-fixed, Paraffin-embedded tissue blocks belonged to patients suffered
from colonic and/or rectal cancers. Patients were admitted to sohag university hospital
and underwent colectomy and their colonic specimens were sent to Pathology Laboratory of
the same hospital to ascertain diagnosis and tumor phenotype, from period Janurary 2021
to December 2022.
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
Specimens from patients with Colorectal Carcinoma. Tissue blocks with sufficient
material. Specimens with sufficient clinical data.
Exclusion Criteria:
Tissue blocks with insufficient, destroyed or necrotic material. Specimens with
insufficient clinical data.
Gender:
All
Minimum age:
35 Years
Maximum age:
90 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Sohag University hospitals
Address:
City:
Sohag
Country:
Egypt
Status:
Recruiting
Contact:
Last name:
Magdy M Amin, Professor
Contact backup:
Last name:
Mera A Fayez, Doctor
Phone:
01224890136
Email:
meraatef@med.sohag.edu.eg
Start date:
January 1, 2021
Completion date:
June 30, 2024
Lead sponsor:
Agency:
Sohag University
Agency class:
Other
Source:
Sohag University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05794737
